Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effects of PosBion® Supplementation on Intestinal Barrier Function in Adults With Irritable Bowel Syndrome

12 novembre 2026 aggiornato da: My Myracle Sdn.Bhd

Effects of PosBion® Supplementation on Barrier-Related Biomarkers in Adults With Irritable Bowel Syndrome

Postbiotic metabolites produced by beneficial bacteria may influence inflammatory responses, mucosal immunity, and host physiological signalling. PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11, derived from Lactiplantibacillus plantarum RS5 and RI11, respectively.

This study will evaluate changes in a panel of salivary biomarkers following 12 weeks of PosBion® supplementation in adults with irritable bowel syndrome (IBS). The biomarkers include myeloperoxidase (MPO), zonulin, lipopolysaccharide (LPS), LPS-binding protein (LBP), cortisol, serotonin, secretory immunoglobulin A (sIgA), lactoferrin, interleukin-8 (IL-8), immunoglobulin E (IgE), immunoglobulin M (IgM), and immunoglobulin G (IgG).

The study will primarily evaluate changes in inflammatory activity, while additional biomarkers will be used to explore mucosal immune, neuroendocrine, immunoglobulin, microbial exposure, and barrier-related responses following supplementation.

Panoramica dello studio

Descrizione dettagliata

Irritable bowel syndrome is a disorder of gut-brain interaction associated with complex alterations in immune activity, gastrointestinal physiology, microbial-host interactions, and mucosal function. Microbial metabolites derived from beneficial bacteria have received increasing attention because of their potential immunomodulatory, anti-inflammatory, antioxidant, and mucosal effects.

PosBion® is a commercially available dietary supplement containing LPM5 and LPM11, proprietary cell-free metabolite preparations derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. The finished preparations do not contain viable or inactivated bacterial cells.

Previous experimental investigations of RS5- and RI11-derived metabolites have demonstrated antimicrobial, antioxidant, immunomodulatory, and intestinal health-related activities. In particular, RI11-derived metabolites have been associated experimentally with modulation of inflammatory cytokines, antioxidant defence, and barrier-associated pathways.

The present study is designed as a prospective, single-arm, open-label interventional study to investigate longitudinal changes in salivary biomarkers following 12 weeks of PosBion® supplementation.

The principal biomarker of interest will be salivary IL-8 as a marker of inflammatory activity. Additional inflammatory markers will include MPO and lactoferrin. Mucosal and adaptive immune responses will be evaluated using sIgA, IgE, IgM, and IgG. Cortisol and serotonin will be investigated as neuroendocrine biomarkers.

Salivary zonulin, LPS, and LBP will also be assessed as exploratory biomarkers potentially related to microbial exposure and barrier-associated processes. Because these biomarkers are measured in saliva, they will not be interpreted as direct measurements of intestinal permeability.

Unstimulated saliva will be collected at baseline and after 4, 8, and 12 weeks of supplementation under standardized collection conditions. Biomarker concentrations will be quantified using commercially available validated assays according to the manufacturers' instructions.

The study is intended to provide mechanistic biomarker data on the biological responses associated with PosBion® supplementation rather than to evaluate changes in IBS symptom severity.

Tipo di studio

Interventistico

Iscrizione (Stimato)

55

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adults aged 18 years or older
  • Experienced one or more symptoms suggestive of irritable bowel syndrome (IBS) prior to enrolment
  • Willing to comply with interventional plan
  • Willing to give consent

Exclusion Criteria:

  • History of chronic or serious medical conditions, including diabetes mellitus, cardiovascular disease, chronic kidney disease, cancer, or chronic respiratory disease
  • Current use of gastrointestinal health supplements
  • Current use of antibiotics or antiviral medications
  • Current use of probiotic, prebiotic, or postbiotic supplements
  • Major surgery within the previous 6 months.
  • Pregnant or lactating woman

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: PosBion® Supplementation

Subjects will consume PosBion® for 12 consecutive weeks. Two sachets will be consumed daily, with one sachet taken after breakfast and one sachet after dinner. Saliva samples will be collected at baseline and Weeks 4, 8, and 12 for biomarker analysis.

PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11 derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. Each sachet contains 2,500 mg LPM5 and 2,500 mg LPM11. Subjects will consume two sachets daily for 12 weeks, with one sachet taken after breakfast and one after dinner. The finished preparations do not contain viable or inactivated bacterial cells.

Altri nomi:
  • PosBion®

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Salivary Interleukin-8 (IL-8) Concentration
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12

Salivary IL-8 concentration will be quantified using an enzyme-linked immunosorbent assay (ELISA). Changes over time will be evaluated, with the principal comparison between baseline and Week 12.

Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12
Change in Salivary Myeloperoxidase (MPO)
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary MPO concentration will be quantified using ELISA as a marker associated with neutrophil and inflammatory activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Lactoferrin
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary lactoferrin concentration will be quantified using ELISA as a marker associated with mucosal innate immune and inflammatory activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Secretory Immunoglobulin A (sIgA)
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary sIgA concentration will be quantified as a marker of mucosal immune activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgE
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary IgE concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgM
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary IgM concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgG
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary IgG concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Baseline, Week 4, Week 8, and Week 12
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary cortisol concentration will be quantified as a neuroendocrine biomarker associated with physiological stress responses.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Serotonin
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary serotonin concentration will be quantified as an exploratory neuroendocrine biomarker.

Baseline, Week 4, Week 8, and Week 12

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Salivary Zonulin
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary zonulin will be quantified as an exploratory biomarker potentially associated with barrier-related processes. The measurement will not be considered a direct assessment of intestinal permeability.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Lipopolysaccharide (LPS)
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary LPS concentration will be evaluated as an exploratory marker of microbial exposure. Changes will not be interpreted as direct evidence of intestinal microbial translocation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary LPS-Binding Protein (LBP)
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12

Salivary LBP concentration will be evaluated as an exploratory biomarker related to host responses to microbial products.

Baseline, Week 4, Week 8, and Week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

15 febbraio 2027

Completamento dello studio (Stimato)

15 marzo 2027

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual-level data underlying the reported study findings, together with relevant data dictionaries, may be made available to qualified researchers following publication.

Periodo di condivisione IPD

Beginning approximately 6 months after publication of the primary study findings and available for up to 5 years.

Criteri di accesso alla condivisione IPD

Data may be provided to qualified researchers who submit a scientifically sound proposal. Requests will be reviewed by the principal investigator and/or study sponsor. Approved access may require a data-use agreement and secure transfer of de-identified data.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi